Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223803 · ClinicalTrials.gov registry record · Phase 2
TERPS Trial for de Novo Oligometastic Prostate Cancer
A Phase 2 study of Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 9
- Study locations
NCT05223803: Recruiting Phase 2 study of Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore.
NCT05223803 is a Phase 2 study of Prostate Cancer and Oligometastatic Disease that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 122 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05223803, a Phase 2 study of Prostate Cancer and Oligometastatic Disease, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 9
- Study locations
Study Summary
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Primary Outcome
Cross-over to the SABR MDT is allowed following failure.
Conditions Studied
Interventions
- RADIATION Prostate radiation (XRT)
- DRUG Systemic Therapy
- RADIATION Stereotactic ablative radiation therapy (SABR)
Study Locations (9)
Maryland
- Maryland Proton Treatment Center - Baltimore
- UMMC - Baltimore
- Upper Chesapeake Health - Bel Air
- Central Maryland Radiation Oncology - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Pennsylvania
- Sidney Kimmel Cancer Center at Jefferson Health - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
California
- UC San Diego Moores Cancer Center - La Jolla
Virginia
- Bon Secours Cancer Institute at St. Francis - Midlothian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
What NCT05223803 shows while recruiting
NCT05223803 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prostate radiation (XRT) is the first listed.
NCT05223803 lists 9 locations in 4 states (Maryland, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT05223803 about?
NCT05223803 is a clinical study titled "TERPS Trial for de Novo Oligometastic Prostate Cancer". This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
What is the current status of trial NCT05223803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2022-10-18. Estimated completion is 2027-07-31.
What conditions does trial NCT05223803 study?
This clinical trial studies the following conditions: Prostate Cancer, Oligometastatic Disease.
What interventions are being tested in trial NCT05223803?
The interventions under investigation include: Prostate radiation (XRT) (RADIATION), Systemic Therapy (DRUG), Stereotactic ablative radiation therapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT05223803?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05223803 being conducted?
This trial has 9 study locations across California, Maryland, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05223803's enrollment target sits among peer trials
122 299th of 735 higher than 436 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
- NCT05168163 · 122 participants · Phase 2
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI